Extrarenal manifestations
| PatientN, Sex | Age at TAC starting (years) | Disease duration(years) | Main indication for TAC | Extrarenal features | Concomitant therapies | Outcome (PGA) |
| 1, M | 18 | 8 | Nephritis | Arthritis, lymphopaenia | GC, HCQ, MMF | Renal: non-responder; Extrarenal: non-responder |
| 2, F | 53 | 13 | Extrarenal | Cytopenia (Evans Syndrome) | GC, HCQ | Non-responder |
| 3, F | 29 | 14 | Extrarenal | Serositis, lymphopaenia, arthritis | GC, HCQ | Complete response at 6 months |
| 4, F | 21 | 5 | Extrarenal | Arthritis, skin rash Cytopenia | GC, HCQ | Complete response at 3 months |
| 5, F | 35 | 10 | Extrarenal | Skin vasculitis | GC, HCQ, MMF, Belimumab | Non-responder |
| 6, F | 63 | 3 | Nephritis | Anaemia, serositis | GC, HCQ, MMF | Complete response at 3 months |
| 7, F | 32 | 13 | Extrarenal | Arthritis | GC, HCQ, MMF | Partial response at 3 months |
| 8, F | 35 | 17 | Nephritis neutropaenia | Neutropaenia | GC, AZA | Partial response at 3 months |
AZA, azathioprine; GC, glucocorticoids; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; TAC, Tacrolimus; PGA, physician global assessment.